Our Scientific Advisory Boards are comprised of thought leaders across a broad range of therapeutic areas and disciplines who have made significant contributions to research, clinical practice, and patient care. Biosplice Therapeutics regularly consults and involves these experts in key decisions to help develop our scientific and clinical programs.

Robert (Bob) Abraham, PhD

Chief Scientific Officer, Vividion Therapeutics

Robert (Bob) Abraham, PhD is the Chief Scientific Officer at Vividion Therapeutics. His major research interests included characterization and functional analysis of the mammalian Target of Rapamycin signaling pathway, cancer metabolism, signal transduction mechanisms in T-lymphocytes, and molecular mechanisms underlying cell proliferation and cellular responses to DNA damage. Bob is the author of over 220 scientific publications and has served on and chaired grant review panels at the National Institutes of Health. His published work has been cited more than 40,000 times. He is a reviewer for many top journals, including Nature, Science, and Cell. He has received several awards for his scientific contributions, including the Legacy Laureate Award as an outstanding alumnus of the University of Pittsburgh.

Bob was the Senior Vice President and Group Head of the Oncology R&D Group in Pfizer Worldwide Research, Development and Medical and Vice President of Oncology Research at Wyeth Discovery Research. Prior to joining industry, Bob was a Professor at the Sanford-Burnham-Prebys Medical Discovery Institute (SBPMDI) in La Jolla, CA, where he founded the Signal Transduction Research Program and served as the Director of the SBPMDI Cancer Research Center. Bob retains an appointment as an Adjunct Professor at the SBPMDI, together with an Adjunct Professor Appointment in Pharmacology at the University of California-San Diego. Bob was a Professor in the Department of Pharmacology and Cancer Biology at the Duke University Medical Center, where he also served as Associate Director of Translational Research in the Duke Comprehensive Cancer Center. Before his arrival at Duke University, Bob was a Professor in both the Department of Immunology and the Department of Pharmacology at the Mayo Clinic in Rochester, MN where he also served as Director of Basic Sciences in the Mayo Comprehensive Cancer Center.

Bob received his B.S. in Biology from Bucknell University and completed his Ph.D. studies in Pharmacology at the University of Pittsburgh and completed a Postdoctoral Fellowship in Pharmacology and Immunology at the Mayo Clinic.

Dafna Bar-Sagi, PhD

Saul J. Farber Professor, Department of Biochemistry and Molecular Pharmacology, Professor, Department of Medicine, Executive Vice President and Vice Dean for Science, and Chief Scientific Officer, NYU Langone Health

Dafna Bar-Sagi, Ph.D., is the Saul J. Farber Professor, Department of Biochemistry and Molecular Pharmacology, Professor, Department of Medicine, Executive Vice President and Vice Dean for Science, Chief Scientific Officer of NYU Langone Health. In these roles, she serves as the principal strategist to advance the NYU Langone’s research enterprise. Additionally, Dr. Bar-Sagi oversees all clinical, translational, and basic science operations, graduate education, and administration for the research enterprise through the Office of Science and Research.

Dr. Bar-Sagi is a world-renowned cancer biologist whose research has had a major impact on the understanding of mechanisms that control tumor initiation and progression. The focus of her work is the Ras oncogene and its role in the regulation of cell proliferation and survival, tumor immunity, cellular metabolism, and cell-to-cell signaling.

Prior to joining NYU Langone in 2006 as chair of the Department of Biochemistry, she headed the Department of Molecular Genetics and Microbiology at the State University of New York (SUNY) at Stony Brook. She earned her undergraduate and master’s degrees from Bar-Ilan University, Israel, and her PhD from SUNY at Stony Brook. She was a postdoctoral fellow in the cell biology group at Cold Spring Harbor Laboratory.

Dr. Bar-Sagi is the recipient of numerous honors and awards, including Member of the National Academy of Sciences (2020-current), IUBMB Jubilee Lectureship Award (2020), Fellow of the American Association for Cancer Research (2019-current), an NCI Outstanding Investigator Award (2016-2023), the AACR-WICR Memorial Award (2018), and an NCI Merit Award (1996-2006). She has been a member of many advisory boards including Chair of the NCI Board of Advisors (2018-2021), Fox Chase Cancer Center External Advisory Council (2017-current), AACR Board of Directors (2016-2019), Pancreatic Cancer Action Network (2010-current), Wistar Institute External Advisory Board (2015-current), Damon Runyon Cancer Research Foundation Board of Scientific Reviewers (2015-current), and the Starr Cancer Consortium Scientific Review Board (2010-current).

Benjamin Cravatt, PhD

Professor and the Norton B. Gilula Chair of Chemical Biology, Department of Chemistry, The Scripps Research Institute

Dr. Cravatt is a Professor and the Norton B. Gilula Chair of Chemical Biology in the Department of Chemistry at The Scripps Research Institute. His research group is interested in developing chemical proteomic technologies that enable protein and drug discovery on a global scale and applying these methods to characterize biochemical pathways that play important roles in human physiology and disease, especially as pertains to the nervous system and cancer. Dr. Cravatt obtained his undergraduate education at Stanford University, receiving a B.S. in the Biological Sciences and a B.A. in History. He then received a Ph.D. from The Scripps Research Institute (TSRI) in 1996. Professor Cravatt joined the faculty at TSRI in 1997. Dr. Cravatt is an Associate Editor for JACS and is a co-founder of Activx Biosciences, Abide Therapeutics, and Vividion Therapeutics. His honors include a Searle Scholar Award, the Eli Lilly Award in Biological Chemistry, a Cope Scholar Award, the ASBMB Merck Award, the RSC Jeremy Knowles Award, the AACR Award for Achievement in Chemistry in Cancer Research, and memberships in the American Academy of Arts and Sciences, National Academy of Medicine, and National Academy of Sciences.

Jeffrey L. Cummings, MD, ScD

Vice Chair for Research and Research Professor, UNLV Department of Brain Health; Director, Center for Neurodegeneration and Translational Neuroscience Cleveland Clinic, Lou Ruvo Center for Brain Health

Jeffrey L. Cummings, MD, ScD, is Vice Chair of Research, UNLV Department of Brain Health. He is Founding Director of the Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas, Nevada, and Professor of Medicine (Neurology), Cleveland Clinic Lerner College of Medicine of Case Western Reserve University. Dr. Cummings is Principal Investigator/Director of the NIH/NIGMS-funded Center for Neurodegeneration and Translational Neuroscience.

Dr. Cummings is a world-renowned Alzheimer’s researcher and leader of clinical trials. He has been recognized for his research and leadership contributions in the field of Alzheimer’s disease through the Henderson Award of the American Geriatrics Society (2006), the Ronald and Nancy Reagan Research Award of the national Alzheimer’s Association (2008), and the Lifetime Achievement Award of the Society for Behavioral and Cognitive Neurology (2017). In 2010, he was honored by the American Association of Geriatric Psychiatry with their Distinguished Scientist Award. In 2018, he was honored with the Leadership and Achievement Award by the International Society of CNS Drug Development, and he received the Bengt Winblad Lifetime Achievement Award from the national Alzheimer’s Association. In 2019, the International Psychogeriatric Association awarded him with the Distinguished Service Award and he received the Alzheimer’s Drug Discovery Foundation’s Melvin R. Goodes Prize that honors an innovative researcher who has made a significant and lasting impact in the field. He was featured in the Gentleman’s Quarterly (June 2009) as a “Rock Star of Science.”

Dr. Cummings’ interests embrace clinical trials, developing new therapies for brain diseases, and the interface of neuroscience and society.

Dr. Cummings completed Neurology residency and a Fellowship in Behavioral Neurology at Boston University, Boston, Massachusetts. US training was followed by a Research Fellowship in Neuropathology and Neuropsychiatry at the National Hospital for Nervous Diseases, Queen Square, London, England. Dr. Cummings was formerly Augustus S. Rose Professor of Neurology and Professor of Psychiatry at UCLA, Director of the Mary S. Easton Center for Alzheimer’s Disease Research at UCLA, and Director of the Deane F. Johnson Center for Neurotherapeutics at UCLA. He is past president of the Behavioral Neurology Society and of the American Neuropsychiatric Association.

Dr. Cummings has authored or edited 43 books and published over 750 peer-reviewed papers.

Frank McCormick, PhD, FRS, DSc (Hon)

Professor, UCSF Helen Diller Family Comprehensive Cancer Center

Frank McCormick, PhD, is a Professor at the UCSF Helen Diller Family Comprehensive Cancer Center. Prior to joining the UCSF faculty, Dr. McCormick pursued cancer-related work with several Bay Area biotechnology firms and held positions with Cetus Corporation (Director of Molecular Biology, 1981-1990; Vice President of Research, 1990-1991) and Chiron Corporation, where he was Vice President of Research. In 1992 he founded Onyx Pharmaceuticals, a company dedicated to developing new cancer therapies, and served as its Chief Scientific Officer until 1996. At Onyx Pharmaceuticals, he initiated drug discovery efforts that led to the approval of Sorafenib in 2005 for treatment of renal cell cancer, and for liver cancer in 2007, and the approval of ONYX-015 in 2006 in China for treatment of nasopharyngeal cancer. In addition, Dr. McCormick’s group led to the identification of the CDK4 kinase inhibitor, Palbociclib, approved for treating advanced breast cancer. Dr. McCormick's current research interests center on ways of targeting Ras proteins and their regulators, including the NF1 protein neurofibromin.

Dr. McCormick holds the David A. Wood Chair of Tumor Biology and Cancer Research at UCSF. He is the author of over 330 scientific publications and holds more than 20 issued patents. Dr. McCormick was Director of the Helen Diller Family Comprehensive Cancer Center from 1997 to 2014. He also served as President, 2012-2013, for the American Association for Cancer Research. Since 2013, Dr. McCormick has led the National Cancer Institute’s Ras Initiative at the Frederick National Laboratories for Cancer Research overseeing the national effort to develop therapies against Ras-driven cancers. These cancers include most pancreatic cancers, and many colorectal and lung cancers, and are amongst the most difficult cancers to treat.

Dr. McCormick is a Fellow of the Royal Society and a member of the National Academy of Sciences.

William C. Mobley, MD, PhD

Associate Dean for Neurosciences Initiatives, Distinguished Professor of Neurosciences, Florence Riford Chair for Alzheimer Disease Research, University of California San Diego School of Medicine

Dr. Mobley is Associate Dean of Neurosciences Initiatives and Distinguished Professor of Neurosciences at UC San Diego. He serves as Executive Director of UCSD's Down Syndrome Center for Research and Treatment, and holds the Florence Riford Chair of Alzheimer Disease Research. He came to UCSD in June 2009 from Stanford University where he served as the John E. Cahill Family Professor in the Department of Neurology and Neurological Sciences and was founding director of the Neuroscience Institute. Dr. Mobley’s research is focused on degenerative disease of the central nervous system, especially Down syndrome and Alzheimer’s disease.

He and his colleagues have for many years explored the hypothesis that deficient axonal transport of neurotrophic factor signals contribute importantly to the pathogenesis of neurodegeneration.

Dr. Mobley serves as the expert advisor to the Congressional Down Syndrome Caucus. He is Past President of the Association of University Professors of Neurology, of the Professors of Child Neurology, and of the International Society for Developmental Neuroscience. He is a Fellow of the Royal College of Physicians and the American Association for the Advancement of Science. He is a member of the National Academy of Medicine. He received both the Zenith Award and Temple Award from the Alzheimer's Association and the Cotzias Award from the American Academy of Neurology. In 2007 he received the Christian Pueschel Memorial Research Award, and in 2011 was honored with the International Sisley-Jérôme Lejeune Prize by the Jérôme Lejeune Foundation for his research contributions to Down syndrome and genetic intellectual disabilities. He was inducted into the Johns Hopkins University Society of Scholars in 2014.

Daniel D. Von Hoff, MD

Physician in Chief and Director of Translational Research, Translational Genomics Research Institute (TGen)

Daniel D. Von Hoff, M.D., F.A.C.P., is currently Physician in Chief, Distinguished Professor Translational Research at TGen (Translational Genomics Research Institute) in Phoenix, Arizona. He is also Senior Consultant, Clinical Investigations for the City of Hope; Chief Scientific Officer for HonorHealth Research Institute; Medical Director of Research, Chief Scientific Officer, US Oncology, and Professor of Medicine, Mayo Clinic.

Dr. Von Hoff's major interest is in the development of new anticancer agents, both in the clinic and in the laboratory. He and his colleagues were involved in the beginning of the development of many of the agents we now use routinely, including: mitoxantrone, fludarabine, paclitaxel, docetaxel, gemcitabine, irinotecan, nelarabine, capecitabine, lapatinib, vismodegibm, nab-paclitaxel, nal-IRI, and others. At present, he and his colleagues are concentrating on the development of molecularly targeted therapies for patients with pancreatic and other advanced cancers.

Dr. Von Hoff has published more than 690 papers, 140 book chapters and over 1400 abstracts. Dr. Von Hoff received the 2010 David A. Karnofsky Memorial Award from the American Society of Clinical Oncology for his outstanding contributions to cancer research leading to significant improvement in patient care.

Dr. Von Hoff was appointed to President Bush's National Cancer Advisory Board in 2004-2010. Dr. Von Hoff is the past President of the American Association for Cancer Research (the world's largest cancer research organization), a Fellow of the American College of Physicians, and a member and past board member of the American Society of Clinical Oncology. He is a founder of ILEX Oncology, Inc. (acquired by Genzyme after ILEX had two agents, alemtuzumab and clofarabine, approved by the FDA for patients with leukemia). Dr. Von Hoff is founder and the Editor Emeritus of Investigational New Drugs - The Journal of New Anticancer Agents; and, past Editor-in-Chief of Molecular Cancer Therapeutics. He is a co-founder of the AACR/ASCO Methods in Clinical Cancer Research Workshop. He is also proud to have been a mentor and teacher for multiple medical students, medical oncology fellows, graduate students, and post-doctoral fellows.

Geoffrey M. Wahl, PhD

Daniel and Martina Lewis Chair and Professor, Gene Expression Laboratory, The Salk Institute; Adjunct Professor, Department of Biology, University of California, San Diego

Geoffrey M. Wahl, the Daniel and Martina Lewis Chair, is a professor in the Gene Expression Laboratory at The Salk Institute and an adjunct professor at the University of California, San Diego in the Department of Biology.

A widely recognized expert in understanding the genetic instability of cancer cells and why tumors become resistant to drugs, Dr. Wahl’s group showed that such instability often results from mutations in key tumor suppressor genes such as p53. His group focuses on how cancer cells reprogram into more primitive, plastic cell states that contribute to intratumoral heterogeneity, a process also impacted by p53. An important emphasis is turning these fundamental findings into therapeutic opportunities to treat cancer more effectively. Dr. Wahl has published nearly 200 articles and reviews related to genetic instability, p53 functions, the control of DNA replication, normal and cancer stem cells, and tumor cell plasticity. His lab has developed many technologies in wide use in molecular and cellular biology.

He is an elected Fellow of the American Association for the Advancement of Science, American Association for Cancer Research and American Academy of Arts and Science. He was appointed as a Susan G. Komen Scholar, and served as President of the American Association for Cancer Research.

Dr. Wahl obtained a B.A. in Bacteriology from the University of California, Los Angeles, a PhD in Biological Chemistry from Harvard University, and was a postdoctoral fellow at Stanford University. He joined The Salk Institute in 1979 and became Professor in the Gene Expression Laboratory in 1989.

Michael A. White, PhD

Chief Scientific Officer, IDEAYA Biosciences

Michael A. White, PhD is the Chief Scientific Officer at IDEAYA Biosciences. His focus is small molecule drug discovery for oncology. With over 2 decades of R&D leadership experience in industry and academia, he is recognized for deep expertise in cell regulation, oncogene mechanism of action, tumor biology, target discovery, technology development and fast-track drug discovery. He has held CSO positions at Biosplice and Pfizer, where he led cross-disciplinary groups to build oncology small-molecule pipelines focused on first-in-class therapies that intercept oncogenic signaling networks, modulate tumor/host interactions and promote productive anti-tumor immune responses. These efforts culminated in numerous INDs within a 5-year span. Prior to joining industry, Mike was Professor of Cell Biology at UT Southwestern Medical Center, Associate Director of Basic Science for the Harold Simmons Comprehensive Cancer Center and founding Director of the UTSW Cancer Intervention and Prevention Discovery training program. His appointments included the Hortense and Morton Sanger Professorship in Oncology, the Sherry Wigley Crow Cancer Research Endowed Chair, and the Grant A. Dove Distinguished Chair for Research in Oncology. In 2015, Mike was a recipient of the inaugural National Institute of Cancer’s Outstanding Investigator Award.

Mike’s academic research focused on oncogene effector networks, the molecular architecture of cellular signaling pathways, functional annotation of cancer genomes, and genomics-guided cancer target discovery. He has authored over 150 publications with over 22,000 citations.

Mike completed his postdoctoral training in cancer biology and signal transduction at Cold Spring Harbor Laboratories in New York. He received his PhD in Biology from the University of North Carolina at Chapel Hill, and his B.Sc. (Hons) from the University of Iowa.

John A. Bergfeld, MD

Senior Surgeon, Department of Orthopaedic Surgery, Cleveland Clinic

John A. Bergfeld, M.D., is the Senior Surgeon, Department of Orthopaedic Surgery at the Cleveland Clinic.

He is a graduate of Bucknell University where he played football, followed by his Medical Doctor degree at Temple University. He did his internship and orthopaedic residency at Cleveland Clinic.

He served in the US Navy as Chief of Orthopaedics of the United States Naval Hospital (Annapolis, Maryland, USA) and US Naval Academy and aboard the USS Dubuque with rank of Commander MC USNR.

Dr. Bergfeld served as Team Physician for the Cleveland Browns NFL, Cavaliers NBA, Cleveland Ballet, and Baldwin Wallace University.

He served as President of:

  • American College of Sports Medicine (ACSM)
  • American Orthopaedic Society for Sports Medicine (AOSSM)
  • International Society of Arthroscopy, Knee Surgery and Orthopaedic Sports Medicine (ISAKOS)

He has trained over 90 post graduate fellows, both Primary Care (Sports and Exercise Medicine) and Orthopaedic/Sports Medicine (known as the Warthog Society). He has published over 90 peer review articles and book chapters. He has served as visiting professor and presented multiple endowed lectureships in the USA and internationally.



  • Thomas A Brady Community Service Award
  • Mr. Sports Medicine
  • Hall of Fame
  • George Rovere Education Award
  • Godfather – Traveling Fellows

City of Cleveland, Ohio USA

  • Five Star General Award – City of Cleveland
  • Lifetime Achievement Award - Greater Cleveland Sports Commission
  • John H. Budd MD Distinguished Membership Award – Northeast Ohio Academy of Medicine Master Educator Award – Cleveland Clinic Outstanding Alumnus Award
  • Cleveland Clinic
  • Bucknell University – Class of 1960
  • Bucknell University Outstanding Alumni Varsity Athlete- 1991
  • Temple University Medical School


  • NFL Trainers Jerry Rhea Award
  • NFL Lifetime Achievement Award
  • USA Rugby Medical Hall of Fame
  • American College of Sports Medicine – Legacy Award
  • NATA Team Physician of the Year
  • Ohio Athletic Trainers Outstanding Physician Award

Honorary Memberships

  • European Society Sports Knee and Arthroscopy (ESSKA)
  • American Medical Society for Sports Medicine (AMSSM)
  • European Federation of Orthopaedic Sports Traumatology (EFOST)
  • International Society of Arthroscopy, Knee Surgery and Orthopaedic Sports Medicine (ISAKOS)
  • Spanish Knee and Sports Medicine Society

Wilma F. Bergfeld, MD, FAAD

Professor of Dermatology and Pathology, Senior Dermatologist & Emeritus Director Dermatopathology, Director, Dermatopathology Fellowship, Departments of Dermatology and Pathology, Cleveland Clinic

Wilma Fowler Bergfeld, MD, FACP is Emeritus Director, and past Director and Co-Director of Dermatopathology, Departments of Dermatology and Pathology and Senior Staff Dermatologist Dermatological Research in the Department of Dermatology, Cleveland Clinic. She also is the Director of the Cleveland Clinic’s Dermatopathology Fellowship and Professor of Dermatology and Pathology, Cleveland Clinic Educational Foundation and Associate Clinical Professor, Department of Dermatology, Case Western Reserve University. She has served as a consultant to the Department of Sports Medicine at The Cleveland Clinic. Dr. Bergfeld’s specialty interests include clinical dermatology (hair disorders, androgen excess, photo aging, and cosmetic dermatology) and dermatopathology.

Dr. Bergfeld completed her undergraduate work at the College of William and Mary in Williamsburg, VA, and is a graduate of Temple University School of Medicine in Philadelphia. She did her dermatology residency at Cleveland Clinic and her Dermatopathology fellowship at Armed Forces of Pathology in Washington DC. She joined the Cleveland Clinic in 1969 as a Clinical Dermatologist, Department of Dermatology and later, after the AFIP Dermatopathology Fellowship in 1972, she was appointed as Head (1977-2007), Dermatopathology, Department of Pathology and in 2007 Co-Director of Dermatopathology, Departments of Dermatology and Pathology and in 2015 Emeritus Director. She has been the Director, Cleveland Clinic’s Dermatopathology fellowship since 1975.

Dr. Bergfeld is a former chair and currently consultant to the FDA Dermatology and Ophthalmology Advisory Committee (1972-current) and a consultant to the Devise advisory committee (2009-current). She is the immediate past President of North American Hair Research Society (2011-2016) and Director, World Congress of Hair Research 2015 Miami, and past 2008-9 President of the American Society of Dermatopathology, 1992 President of The American Academy of Dermatology and past President of the Cleveland Academy of Medicine, the Cleveland Dermatology Society, the Ohio Dermatological Association, and the Women's Dermatological Society. She has served on the Cleveland Clinic’s Board of Governors and Board of Trustees (1992-97), and was the President of the Cleveland Clinic Staff (1990).
Most recently she was elected President American Dermatologic Society 2018, the honorary dermatology society.

Since 1977, she has been a member and the Chair (1990-current) of the Cosmetic Ingredient Expert Panel, an expert panel that determines the safety of cosmetic ingredients. She holds an honorary membership in the American Academy of Dermatology, Women’s Dermatology Society, the Cleveland Dermatology Society, Ohio Dermatological Society, Pacific Dermatologic Association the Canadian Dermatology Society and the Italian Dermatology Society.

In 1996, she received the Women's Dermatological Association Rose Hirschler Award honoring an outstanding physician who has contributed to medicine and dermatology while enhancing the role of women in the Dermatology. She is also the recipient of the American Academy of Dermatology's prestigious Marion B. Sulzberger Award in 1997 and AAD Golden Triangle Award 2000 for Community Service. In 2000, she was the first recipient of the Wilma F. Bergfeld MD Leadership Award, awarded by the Women’s Dermatology Society. In 2005, the Cleveland Academy of Medicine honored her the “John Budd, MD, Distinguished Member Award.” The American Society Dermatopathology in 2007 awarded her the prestige’s “Founders Award” and she was elected 2009 President of the American Society of Dermatopathology. In 2008, she was awarded Maria Duran leadership award and medal by the International Society of Dermatology and in 2010, she received the Samuel J. Zakon Dermatology History Award from the Dermatology History Society. The American Academy of Dermatology awarded her 2012 Master of Dermatology Award. In 2014, she received the Elston B. Helwig MD, Memorial Award and Lectureship from American Society of Dermatopathology.

Her American Academy of Dermatology volunteer activities have included: Chair, Council of Communications and longtime member of the communications committee, original member and long-term member of “Dialogues in Dermatology,” Chair of the Scientific Council (annual meeting committee), Chair of the Volunteer Circle: “Members Making a Difference.” She has also served on several AAD and Women’s Dermatology Society Visionary Committees. Dr. Bergfeld has received many AAD Presidential citations that have included Leadership in AAD Communications and The Volunteer Circle. Since 1995, she has been cited in “Best Doctors in America,” “Top Doctors,” “Top Pathologist,” and in numerous Who’s Who publications.

Dr. Bergfeld is the author of over 632 publications, 4 books and 82 book chapters. She has served on many editorial journal boards and has been a reviewer in the both her professional fields of clinical dermatology and dermatopathology. Other activities include consultant/scientific adviser to many pharmaceutical companies.

On a personal note, Dr. Bergfeld is married to John A. Bergfeld MD, an internationally known Sports Medicine Orthopedic Surgeon at Cleveland Clinic. She is the mother of two daughters, Onee Bergfeld Lowe (deceased) and Sigrid Bergfeld Grieco and grandmother to five granddaughters.

Allan Gibofsky, MD, JD, MACR, FACP, FCLM

Professor of Medicine, Health Policy and Research, Weill Cornell Medicine

Dr. Allan Gibofsky is Professor of Medicine, Health Policy and Research at Weill Cornell Medicine. He is an Attending Physician and Rheumatologist at The New York Presbyterian Hospital and Hospital for Special Surgery, where he is Co-Director of the Clinic for Inflammatory Arthritis.

Dr. Gibofsky received his undergraduate degree from Brooklyn College of the City University of New York, his MD from Weill Medical College of Cornell University and his law degree from Fordham University. He did his internship in Pathology, followed by a residency in Medicine at New York Hospital. He completed a fellowship in Rheumatology/Immunology jointly at Hospital for Special Surgery and at The Rockefeller University. Dr. Gibofsky has authored or co-authored numerous papers and text chapters, primarily on the immunogenetics of rheumatic diseases and legal aspects of medical practice. He is known for his work on mechanisms of host-microbe interactions in rheumatology, and, in particular for his basic and clinical studies on rheumatic fever as well as for his work on therapeutic strategies in the treatment of inflammatory rheumatic diseases.

Currently Secretary-Treasurer of The New York Rheumatism Association, Dr. Gibofsky is past Chair of the Medical & Scientific Committee of the New York Chapter of The Arthritis Foundation and received their Physicians’ Leadership Award. He also served as a member of the local and national Arthritis Foundation Board of Trustees, and was Chair for Professional Education. Dr. Gibofsky has participated in numerous professional and public education programs, nationally and internationally. He is a past President of the American College of Legal Medicine, and is past Chair of the American Board of Legal Medicine. In 2002, Dr. Gibofsky served as President of The American College of Rheumatology. Dr. Gibofsky is a Jonas Salk Scholar of the City University and was named Alumnus of the Year by Brooklyn College.

Dr. Gibofsky is a Master of the American College of Rheumatology, a Fellow of the American College of Physicians and a Fellow of the American College of Legal Medicine.

Morgan Jones, MD, MPH

Staff Surgeon, Department of Orthopaedic Surgery, Cleveland Clinic

Morgan Jones, MD, MPH is a practicing sports medicine orthopaedic surgeon and clinical outcomes researcher with a special interest in the development of post-traumatic osteoarthritis after arthroscopic knee procedures. His research has focused on radiographic changes, including joint space narrowing, after anterior cruciate ligament reconstruction and has been supported by the National Institutes of Health. He attended undergraduate and medical school at the Ohio State University, completed his orthopaedic residency at the Montefiore Medical Center and Albert Einstein College of Medicine in New York, spent a year as a sports medicine fellow at the University of Iowa, and obtained a Masters in Public Health at Harvard University. He currently works as a staff surgeon at the Cleveland Clinic.

Nancy E. Lane, MD

Director, Center for Musculoskeletal Health and Distinguished Professor, University of California at Davis, School of Medicine

Nancy E. Lane, MD is a Distinguished Professor of Medicine, Rheumatology, and Aging Research, Director for the Center for Musculoskeletal Health. She is an internationally recognized scientist in the fields of both osteoporosis and osteoarthritis. Her translational research team has been instrumental in defining the role of glucocorticoids in bone fragility including pioneering a seminal clinical trial to demonstrate that daily injections of the hormone PTH could reverse glucocorticoid-induced osteoporosis. In addition she has uncovered novel genetic variations that predispose individuals to osteoarthritis and has studied novel treatments for osteoarthritis. Her research accomplishments have been recognized by the UC Davis School of Medicine Dean’s Team Science Award (2012), the American College of Rheumatology for the Oscar Gluck Memorial Lecture for outstanding work in Osteoporosis (2011), David Trentham Lectureship and Women in Medicine Lectureship at Harvard Medical School (2013), election to Association of American Physicians (2006) and election to the National Academy of Medicine (2012). Dr. Lane was President of the Board of the United States Bone and Joint Decade (2006-2008), co-led the International Bone and Joint Decade Conference in Washington DC (2010), was elected and served on the council of the American Society of Bone and Mineral Research (2010-2013), and the Orthopedic Research Society, and the Northern California Arthritis Foundation.

Dr. Lane is on the editorial boards of Nature Reviews Rheumatology, Rheumatology (Editorial Board), Seminars in Arthritis and Rheumatism (Associate Editor), Co-editor Arthritis and Rheumatism (2005-2010), and The Journal of Rheumatology; has been named Best Doctors in America annually since 2004, and continues to have an active rheumatology practice.

Rik Lories, MD, PhD

Professor of Rheumatology, Skeletal Biology and Engineering Research Center, KU Leuven

Rik Lories directs the Laboratory for Tissue Homeostasis and Disease that is part of the Skeletal Biology and Engineering Research Center at KU Leuven. He is a consultant physician in the Division of Rheumatology at the University Hospitals Leuven. KU Leuven, the largest and oldest university in Belgium, ranks 40th in the Times Higher Education World 2017 Ranking and tops Reuter’s 2017 ranking of Europe’s most innovative universities.

His research focuses on endogenous tissue responses in the joint with specific attention towards translational questions in chronic arthritis, in particular osteoarthritis, axial spondyloarthritis, and psoriatic arthritis. Currently full Professor (“gewoon hoogleraar”) at KU Leuven, he obtained his medical degree summa cum laude in 1996. He subsequently started specialty training in internal medicine and rheumatology. In 2003, he was certified as rheumatologist. In 2003 he also obtained a PhD in biomedical sciences at KU Leuven. He received PhD (4 years) and Postdoctoral fellowships (6 years) from the Flanders Research Foundation. Rik Lories and his team were the first to demonstrate the key homeostatic role of Wnt signaling in the postnatal joint. The observation that mice in which the Wnt antagonist Frzb has been genetically deleted show increased severity of osteoarthritis pointed the attention of a large research community towards this pathway in particular in osteoarthritis. A recent study on DOT1L in osteoarthritis has identified a novel regulatory mechanism of Wnt signaling in the joint.

He has (co-)authored over 140 publications, including original research reports or reviews in Nature Medicine, Nature Communications, Journal of Clinical Investigation, PNAS, Nature Reviews Rheumatology, Osteoarthritis and Cartilage, Annals of the Rheumatic Diseases and Arthritis and Rheumatology.

Timothy McAlindon, MD, MPH

Natalie V. Zucker & Milton O. Zucker Chair of Rheumatology and Professor, Tufts University School of Medicine; Chief, Division of Rheumatology, Tufts Medical Center

Dr. McAlindon has a 20-year research track in the field of osteoarthritis (OA) and currently has set his goals on the development of simple and inexpensive disease-modifying interventions for osteoarthritis. This has brought a focus on the mechanisms of structural progression, its measurement, and comparative effectiveness testing of potential disease modifying interventions. Dr. McAlindon is one of a small number of investigators developing expertise in highly technological image-based evaluation of osteoarthritis structural progression, such as three-dimensional cartilage volume measurement from MRI, trabecular morphometry from MRI, and subchondral DEXA. Dr. McAlindon currently has NIH-funded research grants evaluating the role of bone in OA progression using periarticular DEXA and MRI-based trabecular morphometry, testing the effectiveness of intra-articular corticosteroids on structural progression of knee OA, and developing an integrated parsimonious quantitative knee OA structural damage outcome measure using MRI. Dr. McAlindon has national and international recognition in the field of osteoarthritis, and is a member of the steering committee of the NIH Osteoarthritis Initiative (OAI), co-principal investigator of its Memorial Hospital of Rhode Island clinical site.